INVESTIGATION OF DIFFERENT LIPID BASED MATERIALS AS MATRICES DESIGNED TO CONTROL THE RELEASE OF A HYDROPHOBIC DRUG
Abstract
The present study was designed to evaluate the effect of different hydrophobic materials and their loading level on the release profile of etoricoxib, a model lipophilic drug, from matrix systems. Matrix tablets of the drug were prepared using compritol, precirol, glyceryl monostearate, cetostearyl alcohol and eudragit as release retarding agents by direct compression process. The resulting monolithic tablets were found to have optimum hardness, uniform thickness, high content uniformity and low friability. All tablet formulations yielded quality matrix preparations with satisfactory tableting properties. Increasing the concentration of hydrophobic materials significantly decreased the friability (from 2.73 to 0.46 in case of eudragit) and subsequently increased the tensile strength (0.237 to 0.908 in case of eudragit) of the formulated tablets. At higher hydrophobic level (50% of the matrix), the rate and extent of drug release was significantly reduced due to increased tortuosity and reduced porosity of the matrix. Compritol imparted the strongest retardation of drug release amongst the selected lipid based materials. In vitro drug dissolution and mathematical modeling were used to characterize drug release rate and extent. The release kinetics was found to be governed by the type and content of hydrophobic materials in the matrix. Numerical fits indicate that the Higuchi square root of time model (TEUD I, TEUD II, TCSA I and TCSA II), Hixson-Crowell cube root model (TGMS I, TCOM I and TPRE I) and Korsemeyer Peppas model (TGMS II, TCOM II and TPRE II) were the most appropriate one for describing the release profile of etoricoxib from hydrophobic matrices. Mathematical modeling indicated that the drug release followed a combination of diffusion and erosion mechanism.
Keywords:
Eudragit, Compritol, Hixson-Crowell cube root model, etoricoxibDOI
https://doi.org/10.25004/IJPSDR.2009.010305References
Miyagawa Y, Okabe T, Yamaguchi Y, Miyajima M, Sato H, Sunada H. Controlled-release of diclofenac sodium from wax matrix granules. Int J Pharm 1996; 138:215-224.
Goodhart FW, McCoy RH, Ninger FC. Release of a water-soluble drug from a wax matrix timed-release tablet. J Pharm Sci 1974; 63(11):1748-1751.
Hariharan M, Wowchuk C, Nkansah P, Gupta VK. Effect of formulation composition on the properties of controlled release tablets prepared by roller compaction. Drug Dev Ind Pharm 2004; 30:565-572.
Hamdani J, Moës AJ, Amighi K. Physical and thermal characterisation of Precirol® and Compritol® as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm 2003; 260:47–57.
Bhagwat DA, Kawtikwar PS, Sakarkar DM. Sustained Release Matrices of Verapamil HCl Using Glyceryl Monosterate and Stearic Acid. Res J Pharm Tech 2008; 1(4):405-409.
Basak SC, Kumar KS, Ramalingam M. Design and release characteristics of sustained release tablet containing metformin HCl. Brazilian J Pharm Sci 2008; 44(3):477-483
Tabandeh H, Mortazavi SA, Guilani TB. Preparation of Sustained-Release Matrix Tablets of Aspirin with Ethylcellulose, Eudragit RS100 and Eudragit S100 and Studying the Release Profiles and their Sensitivity to Tablet Hardness. Iranian J Pharm Res 2003; 2:201-206.
Quadir MA, Rahman MS, Karim MZ, Akter S, Awkat MT, Reza MS. Evaluation of hydrophobic materials as matrices for controlled-release drug delivery. Pak J Pharm Sci 2003; 16(2):17-28.
Agrawal NG, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, Neu DC, Gottesdiener KM. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
J Clin Pharmacol 2001; 41:1106-1110.
Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, Agrawal NG. Absorption, Metabolism, and Excretion of Etoricoxib, a Potent and Selective Cyclooxygenase-2 Inhibitor, in Healthy Male Volunteers.
Drug Metab Dispos 2003; 31:224-232.
Chauhan B, Shimpi S, Paradkar A. Preparation and Characterization of Etoricoxib Solid Dispersions Using Lipid Carriers by Spray Drying Technique.
AAPS PharmSciTech 2005; 6(3):EE405-EE412
Leclercq P, Malaise MG. Etoricoxib (Arcoxia). Rev Med Liege 2004; 59(5):345-349.
Brook DB, Marshall K. Crushing strength of compressed tablets 1: comparison of testers. J Pharm Sci 1968; 57:481-484.
Fell JT, Newton JM. Determination of table strength by diametral test. J Pharm Sci 1970; 59:688-689.
Higuchi T. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52:1145-1149.
Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind Eng Chem 1931; 23:923-931.
Korsmeyer RW, von Meerwall E, Peppas NA. Solute and penetrant diffusion in swellable polymers. II. Verification of theoretical models. J Polym Sci Polym Phys Ed 1986; 24:409-434.
Uhumwangho MU, Okor RS, Adogah JT. Potential of carnuba wax in ameliorating brittle fracture during tableting. Pak J Pharm Sci 2009; 22(1):58-61.
Martin A. Physical Pharmacy, 4th Edn., Waverly International, Maryland 1993, pp. 371-372.
Talukder MM, Michoel A, Rombaut P, Kinget R. Comparative Study on Xanthun Gum and Hydroxypropylmethylcellulose as Matrices for Controlled-Release Drug Delivery I. Int J Pharm 1996; 129:231-241.
Boza A, Caraballo I, Alvarez-Fuentes J, Rabasco AM. Evaluation of eudragit® RS-PO and Ethocel ® 100 matrices for the controlled release of lobenzarit disodium. Drug Dev Ind Pharm 1999; 25 (2):229-233.
Lee PI. Diffusional release of a solute from polymeric matrix-approximate analytical solutions. J Memb Sci 1980, 7:255-275.
Sujja-areevath J, Munday DL, Cox PJ, Khan KA. Release characteristics of diclofenac sodium from encapsulated natural gum mini-matrix formulations. Int J Pharm 1996; 139:53-62.
Published
Abstract Display: 216 
PDF Downloads: 411 
